STOCK TITAN

Hepion Pharmaceuticals Inc - HEPA STOCK NEWS

Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.

Overview

Hepion Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing drug therapies for the treatment of chronic liver diseases. Operating at the intersection of innovative research and clinical development, the company focuses on pleiotropic drug therapies designed to address multiple biochemical pathways implicated in various liver pathologies, including liver fibrosis, hepatocellular carcinoma, and viral hepatitis. Utilizing strategic scientific insights, Hepion concentrates on developing cyclophilin inhibitors and nucleoside phosphonate therapies which are designed to deliver high intracellular concentrations of therapeutic agents.

Pipeline and Therapeutic Focus

The company’s pipeline includes novel therapeutic candidates engineered to disrupt pathological processes in liver diseases. One key area is the development of a pan-cyclophilin inhibitor aimed at modulating multiple pathogenic pathways, thereby offering a multifaceted approach to treatment. Additionally, Hepion is involved in developing antiviral therapies that focus on improving intracellular delivery of active compounds, which is critical in the management of chronic hepatitis B. This dual approach emphasizes both the broad-spectrum management of liver disease complications and the targeted delivery of active antiviral agents.

Business Model and Operational Framework

Hepion Pharmaceuticals Inc operates within a competitive biopharmaceutical landscape by leveraging its specialized research expertise in liver disease. The company generates revenue primarily through milestones in drug development, collaborations, and partnerships aligned with its clinical and commercial strategies. Its business model is built on the integration of advanced biomedical research and clinical trial execution, aiming to broaden therapeutic options for chronic liver conditions.

Industry Context and Competitive Landscape

In the realm of biotechnology and pharmaceutical innovation, companies focused on chronic liver disease must navigate a complex regulatory environment and significant clinical challenges. Hepion distinguishes itself by targeting multiple disease mechanisms, which not only differentiates its therapeutic approach but also addresses the intricate nature of liver pathology. The company faces competition from other biopharmaceutical entities that are also developing treatments for liver diseases; however, its commitment to a multipronged therapeutic strategy provides a unique perspective compared to more traditional, single-target therapies.

Commitment to Research and Clinical Development

At the core of Hepion Pharmaceuticals Inc is an unwavering commitment to research and development. By focusing on pleiotropic drug therapies that intervene in several pathological pathways simultaneously, the company underlines its dedication to innovation and scientific rigor. Its research efforts are designed to provide a deeper understanding of liver disease progression, facilitating the development of therapies that are both scientifically robust and clinically meaningful.

Market Position and Value Proposition

The company’s focus on chronic liver diseases positions it within a niche but crucial segment of the biopharmaceutical industry. With a clear emphasis on addressing core challenges in liver disease treatment, Hepion Pharmaceuticals Inc provides a comprehensive platform of therapies that target complex biochemical processes. This integrated approach forms the cornerstone of its value proposition, emphasizing innovation, clinical significance, and a robust research foundation aimed at offering novel therapeutic options.

Overall, Hepion Pharmaceuticals Inc demonstrates deep industry expertise and a dedication to scientific inquiry, making it an informative case study in the evolving landscape of biopharmaceutical research. The company’s strategic focus on drug therapies for chronic liver diseases reinforces its importance in a competitive field where novel treatments are continually redefining therapeutic possibilities.

Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ: HEPA) has announced a 1-for-50 reverse stock split, effective March 17, 2025, at 4:01 p.m. Eastern Time. The company's shares will begin trading on a split-adjusted basis on March 18, 2025, maintaining its NASDAQ symbol 'HEPA' with a new CUSIP number 426897 401.

The reverse split aims to increase the bid price to meet NASDAQ's $1.00 minimum bid requirement for continued listing. This corporate action will reduce outstanding shares from approximately 54.25 million to 1.08 million. Stockholders approved this measure at the annual meeting on March 10, 2025.

The split will automatically combine every 50 shares into one share, with fractional shares rounded up to the next whole share. This action will not affect stockholders' ownership percentages or voting power, except for minimal changes due to fractional share treatment. Proportionate adjustments will be made to stock options, incentive plans, and outstanding warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.15%
Tags
-
Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ:HEPA) has announced a $9.0 million public offering of 27,692,310 shares of common stock or pre-funded warrants. Each share or warrant comes with two common warrants: a series A and series B, both with an exercise price of $0.40 per share.

The combined offering price is $0.325 per common stock unit and $0.3249 for pre-funded warrant units. The proceeds will be used to repay certain debt and for general corporate purposes, including working capital, operating expenses, and capital expenditures.

The offering, managed by sole placement agent Laidlaw & Company (UK), is expected to close around January 23, 2025. The offering is made pursuant to an effective registration statement on Form S-1 and a related registration statement filed under Rule 462(b).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-58.05%
Tags
-
Rhea-AI Summary

Hepion Pharmaceuticals (NASDAQ: HEPA) has announced the termination of its merger agreement with Pharma Two B . The merger agreement, which was initially entered into on July 19, 2024, has been mutually terminated with no termination fees required from either party. As a result, Hepion has cancelled its special stockholders meeting scheduled for December 12, 2024, and withdrawn the proposals outlined in its Definitive Proxy Statement filed with the SEC on November 8, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
Rhea-AI Summary

Hepion Pharmaceuticals (HEPA) has issued a letter to shareholders urging support for its proposed merger with Pharma Two B at the upcoming Special Meeting on December 12, 2024. The company's board unanimously recommends the merger after reviewing strategic alternatives, citing financial challenges and inability to fund clinical development. The merger would allow shareholders to participate in Pharma Two B's late-stage Parkinson's Disease treatment, P2B001. If the merger fails to receive shareholder approval, Hepion warns of potential Nasdaq delisting and bankruptcy risks due to financial resources. While Pharma Two B doesn't plan to advance Hepion's drug pipeline, Hepion remains committed to attempting to monetize its assets for shareholder benefit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.69%
Tags
-
Rhea-AI Summary

Pharma Two B and Hepion Pharmaceuticals (NASDAQ: HEPA) announced that the SEC has declared effective their merger registration statement on Form F-4. The merger, announced on July 22, 2024, will combine Pharma Two B's P2B001 Parkinson's Disease treatment candidate with Hepion's liver disease portfolio. The transaction is expected to close in Q4 2024, subject to stockholder approvals and other conditions. A special stockholder meeting is scheduled for December 12, 2024, at 9:00 AM ET via webcast. Upon closing, the combined entity will operate as Pharma Two B and trade under the symbol 'PHTB'.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.64%
Tags
-
Rhea-AI Summary

Pharma Two B and Hepion Pharmaceuticals (Nasdaq: HEPA) have filed a registration statement on Form F-4 with the SEC for their proposed merger. The filing contains a proxy statement/prospectus detailing the transaction announced on July 22, 2024. Pharma Two B, developing P2B001 for Parkinson's Disease, aims to go public on Nasdaq through this merger with Hepion, which has been developing treatments for liver diseases including NASH and HCC.

The merger, approved by both companies' boards, is expected to close in Q4 2024, subject to stockholder and regulatory approvals. Post-merger, the combined entity will operate as Pharma Two B and trade under the ticker symbol "PHTB". The transaction is supported by financial advisors A.G.P./Alliance Global Partners for Hepion and Laidlaw & Company (UK) for Pharma Two B, along with respective legal advisors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
Rhea-AI Summary

Pharma Two B, a late-stage clinical company developing P2B001 for Parkinson's Disease, has announced plans to go public through a merger with Hepion Pharmaceuticals (Nasdaq: HEPA). The deal includes a concurrent $11.5 million private placement. Post-merger, Pharma Two B shareholders will own approximately 44.5% of the combined company, Hepion shareholders 7.8%, and new investors 47.7%. The company plans to submit an NDA for P2B001 in the first half of 2026. Hepion has also secured a $2.9 million Senior Unsecured Note from institutional investors. The merger is expected to close in Q4 2024, subject to regulatory and shareholder approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
private placement acquisition
-
Rhea-AI Summary
Hepion Pharmaceuticals has initiated wind-down activities in its Phase 2b ASCEND-NASH Trial due to resource constraints. The trial, evaluating the safety and efficacy of rencofilstat for NASH treatment, had 151 subjects randomized with 80 completing their Day 365 visits. The company plans to explore strategic alternatives following this decision.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.85%
Tags
-
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) appointed Michael Purcell to its Board of Directors, bringing over 37 years of experience in financial advisory services. Purcell's background includes roles at Deloitte & Touche LLP and positions on various company boards. His expertise enhances Hepion's strategic guidance and governance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.92%
Tags
management
Rhea-AI Summary
Hepion Pharmaceuticals, Inc. (HEPA) announces the immediate exercise of an outstanding Series B common stock purchase warrant by an institutional investor, resulting in gross proceeds of approximately $2.0 million. The investor will purchase 980,393 shares of Hepion common stock at a revised exercise price of $2.10 per share. Hepion will issue two new unregistered warrants to the investor, each allowing the purchase of 735,295 shares at an exercise price of $1.91 per share. The transaction is expected to close by February 21, 2024, with net proceeds intended for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.19%
Tags
none

FAQ

What is the current stock price of Hepion Pharmaceuticals (HEPA)?

The current stock price of Hepion Pharmaceuticals (HEPA) is $0.478 as of April 2, 2025.

What is the market cap of Hepion Pharmaceuticals (HEPA)?

The market cap of Hepion Pharmaceuticals (HEPA) is approximately 550.8K.

What is the primary focus of Hepion Pharmaceuticals Inc?

Hepion Pharmaceuticals Inc focuses on developing pleiotropic drug therapies for the treatment of chronic liver diseases, addressing multiple pathogenic pathways.

Which therapeutic areas does the company target?

The company targets chronic liver diseases including liver fibrosis, hepatocellular carcinoma, and chronic hepatitis, utilizing approaches like cyclophilin inhibition and antiviral therapy.

What distinguishes Hepion's drug development approach?

Hepion employs a multifaceted strategy by developing therapies that target several biochemical pathways simultaneously, offering a more comprehensive treatment approach compared to single-target therapies.

How does Hepion Pharmaceuticals generate revenue?

Revenue is primarily generated through milestone achievements in drug development and through strategic partnerships and collaborations within the biopharmaceutical sector.

What role do cyclophilin inhibitors play in their treatment strategy?

Cyclophilin inhibitors are central to Hepion's approach, designed to modulate multiple pathological pathways in liver diseases, thereby providing a broad-spectrum therapeutic benefit.

How does Hepion position itself in the competitive biopharmaceutical market?

By focusing on innovative, multi-target drug therapies for complex liver diseases, Hepion differentiates itself through its comprehensive research efforts and a clinical development strategy that addresses multiple disease mechanisms.

What is the significance of the company’s research and development efforts?

Their R&D efforts underline a commitment to understanding liver disease progression at a molecular level, paving the way for the development of therapies that are both scientifically robust and clinically impactful.

How can Hepion's strategy be described for investors looking for detailed company insights?

Investors can appreciate Hepion’s detailed approach to targeting chronic liver diseases through advanced drug therapies, characterized by a sophisticated understanding of disease mechanisms and robust clinical research.
Hepion Pharmaceuticals Inc

Nasdaq:HEPA

HEPA Rankings

HEPA Stock Data

550.80k
1.06M
1.96%
1.48%
12.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
EDISON